stoxline Quote Chart Rank Option Currency Glossary
Clene Inc. (CLNN)
0.3597  -0.028 (-7.27%)    04-12 16:00
Open: 0.38
High: 0.3823
Volume: 1,170,887
Pre. Close: 0.3879
Low: 0.3395
Market Cap: 46(M)
Technical analysis
2024-04-12 4:48:22 PM
Short term     
Mid term     
Targets 6-month :  0.52 1-year :  0.6
Resists First :  0.45 Second :  0.51
Pivot price 0.4
Supports First :  0.33 Second :  0.28
MAs MA(5) :  0.38 MA(20) :  0.4
MA(100) :  0.42 MA(250) :  0.6
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13.9 D(3) :  16.3
RSI RSI(14): 34.7
52-week High :  1.09 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CLNN ] has closed below the lower bollinger band by 9.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CLNN ] is to continue within current trading range. It is unclear right now based on current values. 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.38 - 0.39 0.39 - 0.39
Low: 0.33 - 0.34 0.34 - 0.34
Close: 0.36 - 0.36 0.36 - 0.36
Company Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Headline News

Tue, 19 Mar 2024
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington - GlobeNewswire

Mon, 18 Mar 2024
Brokers Issue Forecasts for Clene Inc.'s Q1 2024 Earnings (NASDAQ:CLNN) - MarketBeat

Thu, 14 Mar 2024
Clene Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Wed, 13 Mar 2024
Clene Inc. reports results for the quarter ended in December - Earnings Summary - TradingView

Wed, 13 Mar 2024
Breaking Down Clene: 4 Analysts Share Their Views - Clene (NASDAQ:CLNN) - Benzinga

Wed, 13 Mar 2024
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 128 (M)
Held by Insiders 6.791e+007 (%)
Held by Institutions 40.1 (%)
Shares Short 229 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.884e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 841.1 %
Return on Equity (ttm) -52.4 %
Qtrly Rev. Growth 654000 %
Gross Profit (p.s.) -57.09
Sales Per Share -1240.57
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.72
Stock Dividends
Dividend 0
Forward Dividend 262480
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android